“showed a trend”

6.2%, p = 0.02), and showed a trend toward residual malignancy which was not significant (6.8% vs. 2.3% p = 0.16).

Although the GGO model showed a trend toward stratification in the Kaplan–Meier curves, no statistically significant difference was observed (p = 0.16).

At equal seeding density (200,000 cells), cells in 3D-plasma medium showed a trend toward higher proliferation than those in 2D-serum medium (P = 0.16).

Discrimination improved modestly, with an increase in AUC from 0.74 to 0.78; this difference showed a trend toward statistical significance by DeLong’s test (ΔAUC 0.038; P = 0.16).

Kaplan–Meier curves analyzing any one graft with > 50 graft stenosis and mortality showed a trend towards a decrease in the combined endpoint in TAR ( p = 0.16) ( Figure 1 ).

Treatment with TGFβ upregulated MMP1 secretion, and GTX-11m showed a trend to reduce it (IPF p = 0.160, sarcoidosis p = 0.309, HP p = 0.059, control p = 0.144) ( Figure 5C ).

Similar to the older mice on the ‘mixed’ background that we analyzed previously, the average vein diameter for the young 50/50 Loxl1 −/− mice showed a trend towards dilation, compared to that of their Loxl1 +/+ littermates ( P =0.16).

The pooled mean difference in FEV 1 showed a trend toward improvement of 4.13%, (95% CI: −1.61 to 9.88, p =0.16) but it was not statistically significant.

Increased distance to the coeliac trunk showed a trend for decreased pain relief ( p = 0.16).

Anti-mask participants, on the other hand, showed a trend toward negative bias for other-race faces, 95% CI [−15.60 1.77], t (17) = −2.22, p = 0.16, Cohen’s d = −0.524, while for own-race faces, the scores were not different from 0, 95% CI [−8.95 9.04], t (16) = 0.014, p > 0.36, Cohen’s d = 0.003.

Complete MMF withdrawal during hospitalization showed a trend towards a reduced risk of progression to severe COVID-19 (41.7% vs 69.2%; P = 0.16)[ 53 ].

No baseline characteristic identified responder patients; however, the confidence interval showed a trend that patients with FEV 1 <35% predicted were more likely to respond (relative risk 1.67 (95% CI 0.87–3.21) p=0.16).

Treatment of B cells with iberdomide resulted in a significant reduction in the percentage of CD27 + IgD - B cells (iberdomide 8.6±13.9 vs vehicle 34.9±19.3, p=0.028), without reducing the percentage of IgD + CD20 low naïve B cells—if anything, treatment with iberdomide showed a trend towards an increase in the percentage of naïve B cells (iberdomide 45.6±19.9 vs vehicle 30.7±18.9, p=0.160) and led to a significant increase in double negative (DN) CD27 - IgD - B cells considered part of the class-switched memory compartment (iberdomide 45.89±16.7 vs vehicle 29.4±16.2, p=0.015) ( figure 2B, C ).

FA was significantly reduced in C3-C5 of patients (p < 0.001) and showed a trend to decrease in C1-C2 (p = 0.160) ( Fig. 4 A).

Even in the absence of visual input, posterior RSC showed a trend toward larger decoding errors as compared with the anterior subregion (13.4 ± 0.7 cm vs. 20.1 ± 3.8 cm; p = 0.16, anterior vs. posterior, n = 6 vs. 3 sessions; Supplementary Fig. 3B ).

In univariate analysis, the OBR group showed a trend toward longer skeletal-related events-free survival (SRE-FS) than the non-OBR group (median SRE-FS, 26 months vs. 12 months; HR, 0.53; 95% CI, 0.21–1.33; p = 0.16).

1d ) and PKCε also showed a trend towards higher values (1.5 ± 1.5 vs 2.1 ± 1.9 AU, p = 0.16, CPM) at 2 weeks.

toyonensis BCT-7112 T group showed a trend of greater values, for example, villus height per crypt depth of duodenum ( P = 0.16) and ileum ( P = 0.12) compared with those in the control group.

1 , and found that sEPSCs showed a trend towards higher frequency in the inhibitory neurons than in the excitatory neurons (Fig. 3c ; 1.32 ± 0.30 Hz (2 mM, Ext) vs. 3.08 ± 1.16 Hz (2 mM, Int); P = 0.16, unpaired t test).

Among the conventionally high-risk patients as defined by age, stage, histology, and MYCN status ( n = 30) [ 23 , 24 ], PET-UHR ( n = 22) showed a trend of worse 5-year EFS (12% [2%–31%] vs . 38% [6%–72%]; P = 0.16) and OS (24% [6%–47%] vs . 50% [1%–91%]; P = 0.07).

Patients bearing K-ras mutations, showed a trend to a shorter PFS (p:0.051) and no differences in OS (p=0.16).

However, comparisons of sTBI patients and controls showed a trend toward elevated QCTs on the PCL ( F (1,74) = 2.05, p < 0.16) and a significant increase in QCTs on the CFQ ( F (1,74) = 4.95, p < 0.03, η 2 = 0.03).

Since the study of Katz et al used a higher dosage than the other included studies, after its exclusion, the pooling result showed a trend favouring daptomycin (five RCTs, 638 patients, OR=1.39, 95% CI 0.88 to 2.19, p=0.16, I 2 =0; figure 2 D).

Both OrO-staining of liver sections and quantification of lipids in liver homogenates showed a trend towards lower fat content of the ATCC livers as compared with the control mice ( P = 0.16 (OrO staining), P = 0.10 (Triglycerides) and P = 0.18 (Cholesterol) ( Figure 3A–B ).

comparator treatment in the low NfL group (HR = 0.52 [0.28–0.97]; P = 0.039 [log-rank]) and showed a trend for reduced CDP in the high NfL group (HR = 0.65 [0.34–1.21]; P = 0.16 [log-rank]), the latter being limited by sample size (27.4% of ocrelizumab arm, 38.2% of IFN arm at week 24).